New Bill could enhance UK clinical trial regulation
European Pharmaceutical Review
OCTOBER 27, 2023
In the report it was acknowledged that the Bill would introduce a notification scheme for low intervention trials, as well as removing the requirement for individual ‘Suspected Unexpected Serious Adverse Reactions’ (SUSARs) to be reported to all trial investigators.
Let's personalize your content